Genetic variability of HIF1A and response to treatment with cisplatin in combination with pemetrexed or gemcitabine in patients with malignant mesothelioma

1. Franko A, Kotnik N, Goricar K, Kovac V, Dodic-Fikfak M, Dolzan V. The Influence of genetic variability on the risk of developing malignant mesothelioma. Radiol Oncol 2018; 52: 105-11. doi: 10.2478/raon-2018-0004 Franko A Kotnik N Goricar K Kovac V Dodic-Fikfak M Dolzan V. The Influence of genetic variability on the risk of developing malignant mesothelioma . Radiol Oncol 2018 ; 52 : 105 - 11 . 10.2478/raon-2018-0004 Open DOISearch in Google Scholar

2. Rigon M, Mutti L, Campanella M. Pleural mesothelioma (PMe): the evolving molecular knowledge of a rare and aggressive cancer. Mol Oncol 2024; 18: 797-814. doi: 10.1002/1878-0261.13591 Rigon M Mutti L Campanella M. Pleural mesothelioma (PMe): the evolving molecular knowledge of a rare and aggressive cancer . Mol Oncol 2024 ; 18 : 797 - 814 . 10.1002/1878-0261.13591 Open DOISearch in Google Scholar

3. Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev 2015; 24: 115-31. doi: 10.1183/09059180.00007014 Røe OD Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic . Eur Respir Rev 2015 ; 24 : 115 - 31 . 10.1183/09059180.00007014 Open DOISearch in Google Scholar

4. McDonald JC, Asciak R, George V, Rahman NM. Update on biology and management of mesothelioma. Eur Respir Rev 2021; 30: 200226. doi: 10.1183/16000617.0226-2020 McDonald JC Asciak R George V Rahman NM. Update on biology and management of mesothelioma . Eur Respir Rev 2021 ; 30 : 200226 . 10.1183/16000617.0226-2020 Open DOISearch in Google Scholar

5. Zellos L, Christiani DC. Epidemiology, biologic behavior, and natural history of mesothelioma. Thorac Surg Clin 2004; 14: 469-77, viii. doi: 10.1016/j. thorsurg.2004.06.011 Zellos L Christiani DC. Epidemiology, biologic behavior and natural history of mesothelioma . Thorac Surg Clin 2004 ; 14 : 469 - 77 , viii. 10.1016/j. thorsurg.2004.06.011 Open DOISearch in Google Scholar

6. Agency of the Republic of Slovenia for the Environment, Human Health and Ecosystems. [Incidence and mortality of malignant mesothelioma]. [Slovenian]. Ljubljana: ARSO; 2021. Agency of the Republic of Slovenia for the Environment, Human Health and Ecosystems . [ Incidence and mortality of malignant mesothelioma ]. [Slovenian]. Ljubljana : ARSO ; 2021 . Search in Google Scholar

7. Fels Elliott DR, Jones KD. Diagnosis of mesothelioma. Surg Pathol Clin 2020; 13: 73-89. doi: 10.1016/j.path.2019.10.001. Fels Elliott DR Jones KD. Diagnosis of mesothelioma . Surg Pathol Clin 2020 ; 13 : 73 - 89 . 10.1016/j.path.2019.10.001. Open DOISearch in Google Scholar

8. Bianco A, Valente T, De Rimini ML, Sica G, Fiorelli A. Clinical diagnosis of malignant pleural mesothelioma. J Thorac Dis 2018; 10(Suppl 2): S253-61. doi: 10.21037/jtd.2017.10.09 Bianco A Valente T De Rimini ML Sica G Fiorelli A. Clinical diagnosis of malignant pleural mesothelioma . J Thorac Dis 2018 ; 10 ( Suppl 2 ): S253 - 61 . 10.21037/jtd.2017.10.09 Open DOISearch in Google Scholar

9. Sahu RK, Ruhi S, Jeppu AK, Al-Goshae HA, Syed A, Nagdev S, et al. Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies. Front Oncol 2023; 13: 1204722. doi: 10.3389/fonc.2023.1204722 Sahu RK Ruhi S Jeppu AK Al-Goshae HA Syed A Nagdev S Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies . Front Oncol 2023 ; 13 : 1204722 . 10.3389/fonc.2023.1204722 Open DOISearch in Google Scholar

10. Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev 2016; 25: 472-86. doi: 10.1183/16000617.0063-2016 Bibby AC Tsim S Kanellakis N Ball H Talbot DC Blyth KG Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment . Eur Respir Rev 2016 ; 25 : 472 - 86 . 10.1183/16000617.0063-2016 Open DOISearch in Google Scholar

11. Sayan M, Eren MF, Gupta A, Ohri N, Kotek A, Babalioglu I, et al. Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm. Adv Respir Med 2019; 87: 289-97. doi: 10.5603/ARM.2019.0051 Sayan M Eren MF Gupta A Ohri N Kotek A Babalioglu I Current treatment strategies in malignant pleural mesothelioma with a treatment algorithm . Adv Respir Med 2019 ; 87 : 289 - 97 . 10.5603/ARM.2019.0051 Open DOISearch in Google Scholar

12. Štrbac D, Dolžan V. Novel and future treatment options in mesothelioma: a systematic review. Int J Mol Sci 2022; 23: 1975. doi: 10.3390/ijms23041975 Štrbac D Dolžan V. Novel and future treatment options in mesothelioma: a systematic review . Int J Mol Sci 2022 ; 23 : 1975 . 10.3390/ijms23041975 Open DOISearch in Google Scholar

13. Manegold C, Symanowski J, Gatzemeier U, Reck M, von Pawel J, Kortsik C, et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol 2005; 16: 923-7. doi: 10.1093/annonc/mdi187 Manegold C Symanowski J Gatzemeier U Reck M von Pawel J Kortsik C Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma . Ann Oncol 2005 ; 16 : 923 - 7 . 10.1093/annonc/mdi187 Open DOISearch in Google Scholar

14. Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, et al. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy. Int J Clin Oncol 2014; 19: 601-6. doi: 10.1007/s10147-013-0619-5 Toyokawa G Takenoyama M Hirai F Toyozawa R Inamasu E Kojo M Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy . Int J Clin Oncol 2014 ; 19 : 601 - 6 . 10.1007/s10147-013-0619-5 Open DOISearch in Google Scholar

15. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-42.doi: 10.1056/NEJMoa1000678 Temel JS Greer JA Muzikansky A Gallagher ER Admane S Jackson VA Early palliative care for patients with metastatic non-small-cell lung cancer . N Engl J Med 2010 ; 363 : 733 - 42 . 10.1056/NEJMoa1000678 Open DOISearch in Google Scholar

16. Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up? Ann Oncol 2022; 33: 129-42. doi: 10.1016/j.annonc.2021.11.005 Popat S Baas P Faivre-Finn C Girard N Nicholson AG Nowak AK Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up? Ann Oncol 2022 ; 33 : 129 - 42 . 10.1016/j.annonc.2021.11.005 Open DOISearch in Google Scholar

17. Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022; 33: 488-99. doi: 10.1016/j.an-nonc.2022.01.074 Peters S Scherpereel A Cornelissen R Oulkhouir Y Greillier L Kaplan MA First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 . Ann Oncol 2022 ; 33 : 488 - 99 . 10.1016/j.an-nonc.2022.01.074 Open DOISearch in Google Scholar

18. Disselhorst MJ, Quispel-Janssen J, Lalezari F, Monkhorst K, de Vries JF,∙van der Noort V, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 2019; 7: 260-70. doi: 10.1016/S2213-2600(18)30420-X Disselhorst MJ Quispel-Janssen J Lalezari F Monkhorst K de Vries JF ·van der Noort V Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial . Lancet Respir Med 2019 ; 7 : 260 - 70 . 10.1016/S2213-2600(18)30420-X Open DOISearch in Google Scholar

19. Kovač V. Mezoteliomi. [Slovenian]. Onkologija (Ljubljana) 2012; 16: 64-8, 112. Kovač V. Mezoteliomi. [Slovenian] . Onkologija (Ljubljana) 2012 ; 16 : 64 - 8 , 112. Search in Google Scholar

20. Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012; 46: 136-44. doi: 10.2478/v10019-012-0032-0 Kovac V Zwitter M Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients . Radiol Oncol 2012 ; 46 : 136 - 44 . 10.2478/v10019-012-0032-0 Open DOISearch in Google Scholar

21. Kim MC, Hwang SH, Kim NY, Lee HS, Ji S, Yang Y, Kim Y. Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma. BMC Cancer 2018; 18: 819. doi: 10.1186/s12885-018-4720-z Kim MC Hwang SH Kim NY Lee HS Ji S Yang Y Kim Y. Hypoxia promotes acquisition of aggressive phenotypes in human malignant mesothelioma . BMC Cancer 2018 ; 18 : 819 . 10.1186/s12885-018-4720-z Open DOISearch in Google Scholar

22. Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med 2007; 80: 51-60. PMID: 18160990 Ziello JE Jovin IS Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia . Yale J Biol Med 2007 ; 80 : 51 - 60 . PMID: 18160990 Search in Google Scholar

23. Gladek I, Ferdin J, Horvat S, Calin GA, Kunej T. HIF1A gene polymorphisms and human diseases: graphical review of 97 association studies. Genes Chromosomes Cancer 2017; 56: 439-52. Gladek I Ferdin J Horvat S Calin GA Kunej T. HIF1A gene polymorphisms and human diseases: graphical review of 97 association studies . Genes Chromosomes Cancer 2017 ; 56 : 439 - 52 . Search in Google Scholar

24. Lieberman M, Peet A. Marks’ basic medical biochemistry: a clinical approach. 5th edition. Philadelphia: Wolters Kluwer; 2018. Lieberman M Peet A. Marks’ basic medical biochemistry: a clinical approach . 5th edition. Philadelphia : Wolters Kluwer ; 2018 . Search in Google Scholar

25. Taabazuing CY, Hangasky JA, Knapp MJ. Oxygen sensing strategies in mammals and bacteria. J Inorg Biochem 2014; 133: 63-72. doi: 10.1016/j. jinorgbio.2013.12.010 Taabazuing CY Hangasky JA Knapp MJ. Oxygen sensing strategies in mammals and bacteria . J Inorg Biochem 2014 ; 133 : 63 - 72 . 10.1016/j. jinorgbio.2013.12.010 Open DOISearch in Google Scholar

26. Wu LF, Xu GP, Zhao Q, Zhou LJ, Wang D, Chen WX. The association between hypoxia inducible factor 1 subunit alpha gene rs2057482 polymorphism and cancer risk: a meta-analysis. BMC Cancer 2019; 19: 1123. doi: 10.1042/BSR2019241 Wu LF Xu GP Zhao Q Zhou LJ Wang D Chen WX. The association between hypoxia inducible factor 1 subunit alpha gene rs2057482 polymorphism and cancer risk: a meta-analysis . BMC Cancer 2019 ; 19 : 1123 . 10.1042/BSR2019241 Open DOISearch in Google Scholar

27. Zhang Q, Chen Y, Zhang B, Shi B, Weng W, Chen Z, et al. Hypoxia-inducible factor-1a polymorphisms and risk of cancer metastasis: a meta-analysis. PLoS One 2013; 8: e70961. doi: 10.1371/journal.pone.0070961 Zhang Q Chen Y Zhang B Shi B Weng W Chen Z Hypoxia-inducible factor-1a polymorphisms and risk of cancer metastasis: a meta-analysis . PLoS One 2013 ; 8 : e70961 . 10.1371/journal.pone.0070961 Open DOISearch in Google Scholar

28. Ray SK, Mukherjee S. Hypoxia-inducible factors-based single nucleotide polymorphism in breast cancer with more cancer susceptibility. Curr Mol Med 2023; 23: 285-8. doi: 10.2174/1566524022666220513124853 Ray SK Mukherjee S. Hypoxia-inducible factors-based single nucleotide polymorphism in breast cancer with more cancer susceptibility . Curr Mol Med 2023 ; 23 : 285 - 8 . 10.2174/1566524022666220513124853 Open DOISearch in Google Scholar

29. Zupanc C, Franko A, Strbac D, Kovac V, Dolzan V, Goricar K. The association of genetic factors with serum calretinin levels in asbestos-related diseases. Radiol Oncol 2023; 57: 473-486. doi: 10.2478/raon-2023-0061 Zupanc C Franko A Strbac D Kovac V Dolzan V Goricar K. The association of genetic factors with serum calretinin levels in asbestos-related diseases . Radiol Oncol 2023 ; 57 : 473 - 486 . 10.2478/raon-2023-0061 Open DOISearch in Google Scholar

30. Wu F, Zhang J, Liu Y, Zheng Y, Hu N. HIF1α genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC. Cell Physiol Biochem 2013; 32: 1566-76. doi: 10.1159/000356593 Wu F Zhang J Liu Y Zheng Y Hu N. HIF1α genetic variants and protein expressions determine the response to platinum based chemotherapy and clinical outcome in patients with advanced NSCLC . Cell Physiol Biochem 2013 ; 32 : 1566 - 76 . 10.1159/000356593 Open DOISearch in Google Scholar

31. Chen Q, Tian WJ, Huang ML, Liu CH, Yao TT, Guan MM. Association between HIF-1 alpha gene polymorphisms and response in patients undergoing neoadjuvant chemotherapy for locally advanced cervical cancer. Med Sci Monit 2016; 22: 3140-6. doi: 10.12659/msm.897486 Chen Q Tian WJ Huang ML Liu CH Yao TT Guan MM. Association between HIF-1 alpha gene polymorphisms and response in patients undergoing neoadjuvant chemotherapy for locally advanced cervical cancer . Med Sci Monit 2016 ; 22 : 3140 - 6 . 10.12659/msm.897486 Open DOISearch in Google Scholar

32. Zhang Y, Wang J, Li Z. Association of HIF1-α gene polymorphisms with advanced non-small cell lung cancer prognosis in patients receiving radiation therapy. Aging (Albany NY). 2021; 13: 6849-65. doi: 10.18632/aging.202542 Zhang Y Wang J Li Z. Association of HIF1-α gene polymorphisms with advanced non-small cell lung cancer prognosis in patients receiving radiation therapy . Aging (Albany NY) . 2021 ; 13 : 6849 - 65 . 10.18632/aging.202542 Open DOISearch in Google Scholar

33. Khoshinani HM, Afshar S, Najafi R. Hypoxia: a double-edged sword in cancer therapy. Cancer Invest 2016; 34: 536-45. doi: 10.1080/07357907.2016.1245317 Khoshinani HM Afshar S Najafi R. Hypoxia: a double-edged sword in cancer therapy . Cancer Invest 2016 ; 34 : 536 - 45 . 10.1080/07357907.2016.1245317 Open DOISearch in Google Scholar

34. Xia Y, Jiang L, Zhong T The role of HIF-1a in chemo-/radioresistant tumors. Onco Targets Ther 2018; 11: 3003-11. doi: 10.2147/OTT.S158206 Xia Y Jiang L Zhong T The role of HIF-1a in chemo-/radioresistant tumors . Onco Targets Ther 2018 ; 11 : 3003 - 11 . 10.2147/OTT.S158206 Open DOISearch in Google Scholar

35. Hao J, Song X, Song B, Liu Y, Wei L, Wang X, et al. Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 2008; 15: 449-55. doi: 10.1038/cgt.2008.4 Hao J Song X Song B Liu Y Wei L Wang X Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells . Cancer Gene Ther 2008 ; 15 : 449 - 55 . 10.1038/cgt.2008.4 Open DOISearch in Google Scholar

36. Liu B, Liu Q, Song Y, Li X, Wang Y, Wan S, et al. Polymorphisms of HIF1A gene are associated with prognosis of early stage non-small-cell lung cancer patients after surgery. Med Oncol 2014; 31: 877. doi: 10.1007/s12032-014- 0877-8 Liu B Liu Q Song Y Li X Wang Y Wan S Polymorphisms of HIF1A gene are associated with prognosis of early stage non-small-cell lung cancer patients after surgery . Med Oncol 2014 ; 31 : 877 . 10.1007/s12032-014- 0877-8 Open DOISearch in Google Scholar

37. Guo X, Li D, Chen Y, An J, Wang K, Zhuding Xu, et al. SNP rs2057482 in HIF1A gene predicts clinical outcome of aggressive hepatocellular carcinoma patients after surgery. Sci Rep 2015; 5: 11846. doi: 10.1038/srep11846 Guo X Li D Chen Y An J Wang K Zhuding Xu SNP rs2057482 in HIF1A gene predicts clinical outcome of aggressive hepatocellular carcinoma patients after surgery . Sci Rep 2015 ; 5 : 11846 . 10.1038/srep11846 Open DOISearch in Google Scholar

38. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010; 10: 389-402. doi: 10.1038/nrc2867. Correction in Nat Rev Cancer 2010; 10: 523. Ryan BM Robles AI Harris CC. Genetic variation in microRNA networks: the implications for cancer research . Nat Rev Cancer 2010 ; 10 : 389 - 402 . 10.1038/nrc2867 . Correction in Nat Rev Cancer 2010; 10: 523. Open DOISearch in Google Scholar

39. Hu X, Fang Y, Zheng J, He Y, Zan X, Lin S, et al. The association between HIF-1α polymorphism and cancer risk: a systematic review and meta-analysis. Tumor Biology 2013; 35: 903-16. doi: 10.1007/s13277-013-1160-x Hu X Fang Y Zheng J He Y Zan X Lin S The association between HIF-1α polymorphism and cancer risk: a systematic review and meta-analysis . Tumor Biology 2013 ; 35 : 903 - 16 . 10.1007/s13277-013-1160-x Open DOISearch in Google Scholar

40. Li HN, He T, Yong-Jiu Zha, Du F, Liu J, Lin HR, et al. HIF-1a rs11549465 C>T polymorphism contributes to increased cancer susceptibility: evidence from 49 studies. J Cancer 2019; 10: 5955-63. doi: 10.7150/jca.35716 Li HN He T Yong-Jiu Zha Du F Liu J Lin HR HIF-1a rs11549465 C>T polymorphism contributes to increased cancer susceptibility: evidence from 49 studies . J Cancer 2019 ; 10 : 5955 - 63 . 10.7150/jca.35716 Open DOISearch in Google Scholar